AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02288078 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Proton pump inhibitor
Description: PPIs (omeprazole, lansoprazole, etc, as not specified) for prevention of peptic ulcer
Study NCT02288078 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Proton pump inhibitor
Description: PPIs (omeprazole, lansoprazole, etc, as not specified) for prevention of peptic ulcer
Study NCT01945437 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium Sulfate
Description: The magnesium group receive intravenous magnesium sulfate.
Study NCT01529541 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin
Description: Sitagliptin 100mg, tablet, once a day (QD)
Study NCT03669900 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: a minimally invasive surgery (SERI)
Description: The SERI technique (as abbreviated to stand for simple, effective, rapid and inexpensive) was presented by several authors to be a minimally invasive technique since it presents with the same advantages as the percutaneous techniques with less tissue dissection and a need for only temporary hardware, meaning no instrumentation and surgery is performed under direct vision without fluoroscopy
Study NCT00157248 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dabigatran etexilate
Description: dosage used at study start
Study NCT01308112 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: iron
Description: Daily supplementation with iron (60 mg) as ferrous sulphate
Study NCT01308112 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: iron
Description: Daily supplementation with iron (60 mg) as ferrous sulphate
Study NCT04101929 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Patients receive Apatinib 250mg po qd , Treatment repeats every 4 weeks until the disease recurrence or unacceptable toxicity，death or begin a novel therapeutic.
Study NCT04101929 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1 capsule
Description: Patients receive S-1 capsule According to the body surface area \<1.25m2 60mg/d, 1.25 \~ 1.5 m2 80 mg/d, > 1.5m2 100mg/d po bid, taking 7 days, stopping for 7 days, 28 days for 1 cycle, Treatment repeats until the disease recurrence or unacceptable toxicity，death or begin a novel therapeutic.
Study NCT04101929 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Patients receive Irinotecan According to the body surface area of 180 mg/m2, ivgg/90min, once every two weeks. Continuous chemotherapy until the criteria for discontinuation of the drug are met (eg, progression of the disease, intolerance of adverse reactions, or withdrawal of informed consent by the patient).~Because the toxicity of apatinib or irinotecan or tigeol in the chemotherapy regimen meets the withdrawal criteria, the drug can be discontinued alone and the exact duration of the trial treatment recorded.
Study NCT04247464 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fasting
Description: Food intake restriction
Study NCT03702114 — intervention group
Intervention type: DEVICE
Intervention: auricular point detection
Description: This device is only for auricular detection. No additional intervention will be delivered.
Study NCT02999529 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Video
Description: Participants will be asked if they know the meaning of six words related to cancer treatment. Following the interview, participants will watch a video explaining the meaning of the six words. After viewing the video, participants will be re-interviewed about the meaning of the six words.
Study NCT03382301 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciclosporin A preconditioning before renal artery stenosis dilation
Description: Ciclosporin A perfusion (2.5 mg/kg) for 1 hour before renal artery dilation
Study NCT03382301 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NaCl preconditioning before renal artery stenosis dilation
Description: NaCl perfusion (Saline perfusion) for 1 hour (2.5 mg/kg) before renal artery dilation
Study NCT01424514 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB-705498
Description: 12mg intra nasal
Study NCT01424514 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo intra nasal
Study NCT01223469 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Contact force assisted irrigated RF ablation
Description: radiofrequency ablation of atrial fibrillation or SVT
Study NCT02533102 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E7050
Description: 100 mg tablet administered orally
Study NCT03178084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc (UK-427,857) QD + Zidovudine/Lamivudine BID
Description: maraviroc (UK-427,857) 300 mg once daily added to zidovudine/lamivudine (300 mg/150 mg twice daily
Study NCT03178084 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Efavirenz QD + Zidovudine/Lamivudine BID
Description: efavirenz (600 mg once daily) added to zidovudine/lamivudine (300 mg/150 mg twice daily)
Study NCT02658006 — intervention group
Intervention type: PROCEDURE
Intervention: Cardiac surgery
Description: All cardiac surgery procedures
Study NCT00801281 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab 375 mg/m2 i.v. d. 1 q. 21 d.
Study NCT00801281 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Rituximab 375 mg/m2 i.v. d. 1 q. 21 d.
Study NCT00801281 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide 750 mg/m2 i.v. d. 1 q. 21 d.
Study NCT00801281 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Cyclophosphamide 750 mg/m2 i.v. d. 1 q. 21 d.
Study NCT00801281 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Doxorubicin 50 mg/m2 i.v. d. 1 q. 21 d.
Study NCT00801281 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Vincristine 1.4 mg/m2 (max. 2 mg) i.v. d. 1 q. 21 d.
Study NCT00801281 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine
Description: Vincristine 1.4 mg/m2 (max. 2 mg) i.v. d. 1 q. 21 d.
Study NCT00801281 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone 1
Description: Prednisone 100 mg p.o. d. 1-5 q. 21 d.
Study NCT00801281 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone 2
Description: Prednisone 40 mg/m2 p.o. d. 1-5 q. 21 d.
Study NCT02953587 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Oral Glucose Tolerance Test (OGTT)
Description: Subjects will have glucose administered enterally and blood will be drawn to measure its kinetics.
Study NCT02953587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human Ghrelin
Description: Human ghrelin will be administered by IV at two of the four study visits in conjunction with the OGTT.
Study NCT02953587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline
Description: Saline Infusion will be administered by IV at two of the four study visits in conjunction with the OGTT to serve as a placebo comparator for the human ghrelin infusions.
Study NCT02951221 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB074 Treatment A
Description: Lower dose RCF fasted
Study NCT02951221 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB074 Treatment B
Description: Lower dose DCF fasted
Study NCT02951221 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB074 Treatment C
Description: Higher dose DCF fasted
Study NCT02951221 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB074 Treatment D
Description: Higher dose DCF fed
Study NCT01097421 — intervention group
Intervention type: DRUG
Intervention: Pramipexole Extended Release
Study NCT05528198 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Montelukast sodium oral thin films without water (A)
Description: Single-dose montelukast sodium oral thin film 5mg under fasted condition without water
Study NCT05528198 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Montelukast sodium oral thin films with water (B)
Description: Single-dose montelukast sodium oral thin film 5mg under fasted condition with water 240 mL
Study NCT05528198 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Montelukast sodium chewable tablets with water (C)
Description: Single-dose montelukast sodium chewable tablet 5mg under fasted condition with water 240 mL
Study NCT00916344 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EVIA Pacemaker
Description: patient has standard indication for pacemaker therapy
Study NCT04669951 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: uPAR immunohistochemistry
Description: Resected esophageal cancer will be qualitatively and semi-quantitatively analyzed for uPAR expression
Study NCT00972816 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MF59-eH1N1
Description: MF59 adjuvanted with egg-derived A/H1N1 antigen. MF59-eH1N1 vaccine is the same vaccine as A/H1N1-SOIV (Swine Origin A/H1N1 Influenza Virus).
Study NCT06451289 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Head computered tomography
Description: Retrospective data collecting from medical records
Study NCT03783130 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-HIVRGP096-00-VP
Description: Trimer 4571 drug product is an investigational HIV vaccine which mimics the native HIV-1 envelope complex. This soluble HIV-1 envelope product consists of an HIV-1 envelope (Env) trimer variant, derived from clade A, strain BG505, with stabilizing mutations and engineered disulfide bonds, specifically recognized by broadly neutralizing antibodies and resists gp120 conformational change caused by CD4 binding.
Study NCT03783130 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alum Adjuvant
Description: Adjuvant is an aluminum hydroxide suspension (alum) mixed with Trimer 4571 to improve the immune response to the investigational vaccine.
Study NCT01609166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allopurinol
Description: Allopurinol 3% cream application in one side of the body, twice a day for 6 months
Study NCT01609166 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo cream application in the other side of the body, twice a day for 6 months
Study NCT04085224 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Somatropin
Description: LG Somatropin
Study NCT04085224 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Somatropin
Description: LG Somatropin
Study NCT00522535 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open surgical repair
Description: Open surgical repair of abdominal aortic aneurysm
Study NCT00522535 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stent Graft
Description: Endovascular repair of abdominal aortic aneurysm (EVAR)
Study NCT02467257 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Gum Arabic
Description: oral ingestion of 30 gram every day for 12 weeks
Study NCT00373958 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 13 valent pneumococcal conjugate vaccine
Description: 1 single 0.5 mL dose together with a concomitant dose of Pediarix and ActHIB at the 2-, 4-, and 6-month visits and ProQuad, PedvaxHIB, and VAQTA at the 12-15 month visit.
Study NCT00373958 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 7vPnc pneumococcal conjugate vaccine
Description: 1 single 0.5 mL dose together with a concomitant dose of Pediarix and ActHIB at the 2-, 4-, and 6-month visits and ProQuad, PedvaxHIB, and VAQTA at the 12-15 month visit.
Study NCT03163056 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive-behavioral treatment (CBT)
Description: The CBT was implemented in group-based sessions of four patients. Sessions were carried out once a week over a 8-week period, with quite date occurring at fifth session. The main component was nicotine fading. From the first to the fourth week, patients were asked to gradually reduce their nicotine intake based on a weekly reduction of 30%. A maximum number of cigarettes per day and also specific cigarette brands with lower nicotine levels were recommended. Other components of the CBT program included information about tobacco, a behavioral contract, self monitoring and graphical representation of cigarette smoking, stimulus control, strategies for controlling nicotine withdrawal symptoms, physiological feedback, training in alternative behaviors, and relapse prevention strategies.
Study NCT03163056 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Cognitive-behavioral treatment (CBT)
Description: The CBT was implemented in group-based sessions of four patients. Sessions were carried out once a week over a 8-week period, with quite date occurring at fifth session. The main component was nicotine fading. From the first to the fourth week, patients were asked to gradually reduce their nicotine intake based on a weekly reduction of 30%. A maximum number of cigarettes per day and also specific cigarette brands with lower nicotine levels were recommended. Other components of the CBT program included information about tobacco, a behavioral contract, self monitoring and graphical representation of cigarette smoking, stimulus control, strategies for controlling nicotine withdrawal symptoms, physiological feedback, training in alternative behaviors, and relapse prevention strategies.
Study NCT03163056 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBT+Behavioral Activation (BA)
Description: This intervention was provided as in the above CBT condition, that is, eight group-based sessions of four patients. Nevertheless, this treatment included a BA component for addressing both smoking cessation and depression management. The BA module included: treatment rationale, information on the relationship between smoking and depression, identification of life areas, values and activities, generation of meaningful and reinforcing activities, social support (i.e., behavioral contracts).
Study NCT03163056 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBT+BA+ Contingency Management (CM)
Description: This intervention was provided in the same manner as the above mentioned treatment protocols but with the addition of a contingency management procedure reinforcing abstinence since fifth session and onwards. The number of sessions was the same as in the aforementioned treatment conditions and CO and cotinine samples were also collected. Participants providing negative specimens of both CO (≤4 ppm) and cotinine (≤80 ng/ml) earned points exchangeable for rewards (e.g., cinema tickets) on a schedule of escalating magnitude of reinforcement (from 10€ voucher value with maximum possible earnings of 175€ in vouchers).
Study NCT02893176 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: macitentan
Study NCT02893176 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo (for macitentan)
Study NCT02784626 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Intraoperative sedation using dexmedetomidine
Study NCT02784626 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Intraoperative sedation using propofol
Study NCT01949441 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ToleroMune HDM
Description: Intradermal injection 1 x 4 administrations 4 weeks apart
Study NCT01949441 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intradermal injection 1 x 4 administrations 4 weeks apart
Study NCT03613883 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endovascular management
Description: Embolic materials (coils / glue): the glue will be routinely used when access into the aneurysm's outflow vessel will be unattainable.~Endovascular stent to slow the flow inducing thrombosis of the sac of aneurysm. CT angiography will be performed later to evaluate and confirm the diagnosis and viability of the endovascular procedure
Study NCT00819780 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: Panitumumab is a fully human immunoglobulin G (IgG)2 monoclonal antibody antagonist directed against human Epidermal Growth Factor receptor (EGFr).
Study NCT00819780 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Bevacizumab is a humanized monoclonal IgG1 antibody that is directed against Vascular Endothelial Growth Factor (VEGF).
Study NCT03178084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc (UK-427,857) BID + Zidovudine/Lamivudine QD
Description: maraviroc (UK-427,857) 300 mg twice daily added to zidovudine/lamivudine (300 mg/150 mg twice daily
Study NCT01770990 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tel-PT including mail
Description: Patients receive telephone-based psychotherapy and one letter after each telephone session.
Study NCT01770990 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Tel-PT without mail
Description: Patients receive telephone-based psychotherapy without additional letters.
Study NCT02349724 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Anti-CEA-CAR T
Description: T cells modified with CEA targeted chimeric antigen receptor.
Study NCT02191384 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orcinoside
Description: oral, twice per day
Study NCT02191384 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Orcinoside
Description: oral, twice per day
Study NCT01494714 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ 10229570-AAA 1.2% cream
Description: A patch containing the cream will be applied on the back and left for 48 hours on the left side, and 24 hours on the right side.
Study NCT01494714 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ 10229570-AAA 2.4% cream
Description: A patch containing the cream will be applied on the back and left for 48 hours on the left side, and 24 hours on the right side.
Study NCT01494714 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ 10229570-AAA 3.6% cream
Description: A patch containing the cream will be applied on the back and left for 48 hours on the left side, and 24 hours on the right side.
Study NCT01494714 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Color-matched vehicle in a cream formulation containing 0 mg of JNJ 10229570-AAA
Description: A patch containing the cream will be applied on the back and left for 48 hours on the left side, and 24 hours on the right side.
Study NCT01494714 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Petroleum jelly
Description: A patch containing the petroleum jelly will be applied on the back and left for 48 hours on the left side, and 24 hours on the right side.
Study NCT03230422 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: normal airway
Description: The Time interval between the laryngoscope blade passing the teeth/gums to the announcing of the first ventilation was recorded as the time to ventilation with the Video laryngoscopy (VL) or conventional direct laryngoscopy (DL)
Study NCT03230422 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: difficult airway
Description: The Time interval between the laryngoscope blade passing the teeth/gums to the announcing of the first ventilation was recorded as the time to ventilation with the Video laryngoscopy (VL) or conventional direct laryngoscopy (DL)
Study NCT02550873 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PRM-151
Description: PRM 151 10 mg/kg IV infusion over 60 minutes days 1, 3, and 5, then one infusion every 4 weeks
Study NCT02550873 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo IV infusion over 60 minutes on days 1, 3, and 5, then one infusion every 4 weeks
Study NCT00798486 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: A1C Test Kit
Description: Subjects tested 3 times with A1C test kits. Two tests were performed by the subject and the third test was performed by a healthcare professional (HCP). All results were compared to results from a laboratory glucose analyzer (TOSOH).
Study NCT04545216 — intervention group
Intervention type: OTHER
Intervention: Long-distance mountain running
Description: Impact of a mountain race on the knee cartilage
Study NCT04657523 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Investigational Liver Fat Quantification Software
Description: All subjects enrolled in this study will undergo two abdominal ultrasound examinations using the investigational Liver Fat Quantification feature on the Philips EPIQ Ultrasound System. In addition, all subjects will also undergo one MRI-PDFF examination according to the clinical standard of care.
Study NCT04320615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab (TCZ)
Description: Participants will receive 1 dose of IV TCZ. 1 additional dose may be given if clinical symptoms worsen or show no improvement.
Study NCT00819780 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mFOLFOX6
Description: mFOLFOX6 regimen is a combination therapy of oxaliplatin (85 mg/m\^2) administered as a 2-hour infusion on Day 1; leucovorin (400 mg/m\^2) administered as a 2-hour infusion on Day 1; followed by a loading dose of 5-fluorouracil (5-FU; 400 mg/m\^2) IV bolus administered over approximately 2 to 4 minutes on Day 1, then 5- FU (2400 mg/m\^2) via ambulatory pump administered for a period of 46 to 48 hours.